Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bioscience Posts 63 Percent Revenue Growth for Q2

NEW YORK, July 28 - Harvard Bioscience today reported year-over-year revenue growth of 63 percent for the second quarter of 2003, after favorable foreign exchange effects, accompanied by a 25 percent decline in net income.


The company posted $22.4 million in revenues for the quarter ended June 30, 2003, up from $13.7 million for the year-ago period. Excluding favorable foreign exchange effects of approximately $865,000, revenue for the second quarter grew 57 percent.


Net income for the second quarter of 2003 was $743,000 on a GAAP basis, compared with $1.0 million for the second quarter of 2002. Second-quarter net income included charges for non-cash stock compensation expense of $134,000 and $331,000 and amortization of intangibles of $729,000 and $307,000 for 2003 and 2002, respectively, before tax, as well as charges of $205,000 related to the acquisitions of Genomic Solutions, BTX, and GeneMachines.


Net income for the second quarter also included a one-time charge of $815,000 for an arbitration award in favor of the former shareholders of Union Biometrica. The charge contributed a $0.01 per-share impact for the quarter, bringing basic and diluted per-share net income for the quarter to $0.02, compared to $0.04 for the second quarter of 2002.


Excluding stock compensation expense and amortization of intangibles, pro forma net income totaled $1.9 million for the second quarter of 2003 compared to $1.5 million for the second quarter of 2002.


Harvard Bioscience incurred $1.7 million in R&D expenses for the second quarter of 2002, up slightly from last year's $1.0 million. The company said that approximately $800,000 of its second-quarter R&D expenses were related to acquisitions completed since the second quarter of 2002.


The company ended the quarter with cash and cash equivalents of $9.2 million, a decrease of approximately $6.1 million since December 31, 2002. $1.3 million in cash was used during the quarter in settlement of a dispute between the company's Genomic Solutions subsidiary and Affymetrix.


Harvard Biosciences is currently negotiating a $25 million revolving credit facility.


Full details of the company's second-quarter earnings, including information on a conference call scheduled for 1:00 EDT tomorrow, are available here.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.